We are live on ! Find out more
EWTX icon

Edgewise Therapeutics

71 hedge funds and large institutions have $523M invested in Edgewise Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

257% more capital inflows, than outflows

Capital inflows: $64.2M | Capital outflows: $18M

39% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 18

22% more funds holding

Funds holding: 58 → 71 (+13)

6.89% more ownership

Funds ownership: 102.09% → 108.98% (+6.9%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
71
Holders Change
+13
Holders Change %
+22.41%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
17
Increased
25
Reduced
18
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

EWTX Hedge Fund Activity: Q1 2022 in Review

71 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q1 2022, worth a combined $523M — down 32% from $769M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new EWTX positions and 4 closed out — a net gain of 13 holders — while 25 added to existing stakes and 18 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $14.4M. The largest seller was Logos Global Management, cutting an estimated $8.19M.

  • 71 institutional investors held Edgewise Therapeutics (EWTX) as of Q1 2022, up from 58 in Q4 2021.
  • Funds reported $523M of Edgewise Therapeutics stock for Q1 2022, down 32% quarter-over-quarter.
  • 17 funds opened new Edgewise Therapeutics positions in Q1 2022 and 4 closed out, a net change of +13 holders.
  • The largest Edgewise Therapeutics buyer in Q1 2022 was Cormorant Asset Management, an estimated $14.4M added.
  • The largest Edgewise Therapeutics seller in Q1 2022 was Logos Global Management, an estimated $8.19M sold.

Based on aggregated 13F filings for Q1 2022.